presents one of the next major public health challenges. Genital chlamydia rates are showing a gra dual decline in most jurisdictions but remain unacceptably high , especially in adolescents and young adults (1 , unpublished data). The much higher rates in young females than in males is a reflection of testing and detection, and is probably not a real difference in epidemiology. The long term consequences of chlamydial infection are well described. The final report of the Royal Commission on New Reproductive Technologies recognized STD, especially chlamydia, to be fue single most important preventa ble cause of infertility in Canada (2) .
Chlamydial infections should be amenable to traditional measures of STD control because accurate diagnostic tests are widely available, and curative therapy is inexpensive and reasonably well tolerated. However, there are problems unique to the control of chlamydial infection: a large reservoir of asymptomatic infection; a long duration of infectiousness; and poor compliance with a seven-day course of antimicrobial therapy, partly beca use symptoms (when present) may resolve after three to four days. Targeted screening of those likely to comprise the reservoir of subclinical infection, eg, sexually active adolescents and young adults. has been recommended in STD guidelines (3) directed to primary care providers. The drawback has been fuat nonculture antigen detection type diagnostic tests, which h ave reasonable performance characte1istics in symptomatic individuals, lack the sensitivity required for a population-based screening test (4) . fuis being especially tru e in a symptomatic men. The use of enzyme linked immunoassay tests on first void urine specimens was intended to increase the ease of testing and screening men, but as yet, the sensitivity of these tests has been variable. Field evaluations have shown sensitivities ranging from 38 to 100% and specificities from 86 to l 00% (5-9).
The recent introduction of molecular amplification techniqu es for the detection of Chlamydia trachomaLis, such as polymerase chain reaction and ligase chain reaction assays, will probably result. in a substantial improvement in the laboratory diagnosis of gerutal infections. As diagnostic and screening tests, they have been shown to offer performance characteristics equivalent. to culture but. are more rapid and have no special transport. requ irements (10, 11) . These techniques also have the advantage of offering 'multipl ex' assays when more than one pathogen that produces similar clinical signs and symptoms, eg, C trachomaLis or Neisseria gonoTThoeae, can be detected using a single specimen. However, inherent. in the exquisite sensitivity of thes e a mplification techniques is the potential for fa lse positive results due to contamination. Crossconta mina tion between specimens , especially after amplification , and run-to-run contamination due to contamina tion of equipment., reagents and supplies, create problems in specimen handling and processing in a routine diagnostic laboratory. Field evaluations have also shown that some amplification reactions may be susceptible to inhibitory substances in the specimen , s u ch a s heme (from a bloody specimen), heparin and phosphate ions. Efforts to adapt. these new technologies for routine use are ongoing. For the present, b eca use of the psychosocial and medicolegal implications of a positive test for STD, a confirmatory assay for chlamydia! infection is strongly recommended.
Th e third issue noted above is compliance with therapy. There is now more evidence of the effectiveness of quinolones, eg, ofloxacin (12) . in the treatment of genital chlamydia. When the Canadian sm Guidelines (4) are reviewed in 1994/95, the position of the quinolones will no doubt. be reconsidered. However, multiple doses are still required. It seems likely that. the azalide, azithromycin (13), will be available in Canada in 1994. Azithromycin has t.he advantage of only requiring a single oral dose of 1 g for treatment due t.o ils tissue retention time of five lo seven days. This is important. in the treatment. of an intracellular organism such as C trachomatis when other drugs have only good therapeutic ratios m easured in terms of hours. There is good evidence from s eve ral clinical trials that. single-dose azithromycin is equivalent to a seven-day regimen of tetracyclines (14) (15) (16) . However, azithromycin is not. highly efficacious against N gonoTThoeae at the same dosage , and therefore two-drug therapy against. combined infections would still be necessary. The effectiveness of azithromycin in cases of urethritis not. caused by N gonoTThoeae or C trachomatis also has lo be taken into account.. Recent studies have not examined efficacy against specific organisms and only evaluate on the basis of a c hange in polymorphonuclear cell counts on Gramstained smears (17 , 18) .
At. first sight the availabili ty of a single-dose treatment. for c hlamydia seems to present. the possibility of much greater success in ch lamydia! control, especially wh en compliance with tetracyclines and macrolides is demonstrably poor. However. we should be cautious. Katz eta! (19) s howed a compliance rate of63.4% in STD clinic clients treated for chlamydia! infection, but Grob (20) cautions that. compliance is dependent on four factors: the patient, the physician, the severity of the disease, and the frequency and duration of therapy. Physicians may be a bl e to do more in counselling patients to encourage compliance, especially by emphasizing the long term consequ ences of disease. Whatever the costs of tetracyclines to governments and individuals, azithromycin will inevitably be more expensive initially. Comparison of costs with effectiveness has lo lake into account many factors, including compliance, requirements for retreatment, further contact tracing, transmission of infection from partially treated persons and long term effects of partially treated disease. If the rate of reporting of chlamydia! infections continues to fall as a result of current control methods, then it. is likely that newer, more expensive therapies shou ld perhaps be considered as a second-line choice, except. in situations where compliance is a major issue and where the extent of risky sexual behaviour is such that. the aggressive use of a single-dose therapy for cases and contacts is justified. Therefore, the rate of infection and the circumstances of infection may have to be taken into account. Although structurally related to the macrolides, eg, erythromycin , azithromycin will likely be contraindicated in pregnancy due to lack of toxicological data. This will have to be taken into account. in populations at high risk where the possibility of pregnancy may be increased.
Gem; et al (21) carried out. an economic evaluation of screening for C trachomatis in adolescent males and concluded that, in combination with a single dose of azit.hromycin, urine screening using an enzyme irnmunoassay with or without. leukocyte esterase testing improved cure rates and reduced costs. They note that. the use of polymerase chain testing of urine would be less attractive due to laboratory contamination issues and cost. This study reflects the dilemma that public health practitioners are facing today. For the first time, we have very sensitive molecular techrllques for screening and a single-dose drug that can help us overcome major problems in chlamydia control, but these innovations will cost. five to 10 times more than conventional methods of diagnosis and therapy. These advances will, in our opinion, ultimately result in significantly reduced health care costs as a result of a reduction in expensive long t.em1 sequelae. We need to debate whether we can afford not. to use these aids to chlamydia control and in what circumstances they can be used most. cost-effectively.
